FDA's procedures for overseeing recalls are unclear. As a result, FDA officials examining similar situations sometimes reached opposite conclusions on whether recalls were effective. FDA had also not established criteria, based on the nature or type of devices, for assessing whether firms corrected or removed a sufficient number of recalled devices.
Additionally, FDA's decisions to terminate completed recalls — that is, assess whether firms had taken sufficient actions to prevent a recurrence of the problems that led to the recalls — were frequently not made within its prescribed time frames.
Finally, FDA did not document its justification for terminating recalls. If unaddressed by FDA, the combined effect of these gaps may increase the risk that unsafe medical devices could remain on the market. To aid its oversight of the medical device recall process, FDA should routinely assess information on device recalls, develop enhanced procedures and criteria for assessing the effectiveness of recalls, and document the agency's basis for terminating individual recalls. HHS agreed with GAO's recommendations.
Recommendation
To enhance FDA's oversight of medical device recalls, and in particular, those medical device recalls that pose the highest risk, the Commissioner of FDA should create a program to routinely and systematically assess medical device recall information, and use this information to proactively identify strategies for mitigating health risks presented by defective or unsafe devices. This assessment should be designed, at a minimum, to identify trends in the numbers and types of recalls, devices most frequently being recalled, and underlying causes of recalls.
Agency Affected: Department of Health and Human Services: Food and Drug Administration
Status: In process
Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Pages: 1 · 2
More Articles
- A Yale Medicine Doctor Explains How Naloxone, a Medication That Reverses an Opioid Overdose, Works
- Indoor and Vertical Farming May Be Part of the Solution to Rising Demands for Food and Limited Natural Resources
- Kaiser Health News: Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
- GAO*, Pipeline Safety: Performance Measures Needed to Assess Recent Changes to Hazardous Liquid Pipeline Safety Regulations
- Kaiser Family Foundation: FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
- Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic
- Testimony: Assault in the Military, Continued Congressional Oversight and Additional DOD Focus on Prevention Could Aid DOD's Efforts
- GAO: COVID-19 Complicates Already Challenged FDA Foreign Inspection Program; It Could Be 2 to 3 Years Before New Staff Are Experienced Enough To Conduct Foreign Inspection
- From the CDC (Centers for Disease Control and Prevention) For the Public: What You Need to Know About Vaping
- Vincristine Shortage – Update and Action To the Childhood Cancer Community